Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.70 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.70 |
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.56 |
| ▸ | VEGFA | P15692 | 4/20 | 0.55 |
| ▸ | FLT1 | P17948 | 4/20 | 0.55 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25934739 | 0.87 | EGLN2 (0.65) | EGLN2FTOEGLN1VEGFAFLT1 | |
| SCHEMBL25934858 | 0.87 | FTO (0.65) | EGLN2FTOEGLN1VEGFAFLT1 | |
| SCHEMBL1921385 | 0.87 | EGLN2 (0.65) | EGLN2FTOEGLN1TLR7 | |
| SCHEMBL8149752 | 0.86 | EGLN2 (0.63) | EGLN2FTOEGLN1VEGFAFLT1 | |
| SCHEMBL8135880 | 0.85 | EGLN2 (0.62) | EGLN2FTOEGLN1VEGFAFLT1 | |
| SCHEMBL25934714 | 0.84 | FTO (0.74) | EGLN2FTOEGLN1VEGFAFLT1 | |
| SCHEMBL8149317 | 0.84 | FTO (0.64) | EGLN2FTOEGLN1VEGFAFLT1 | |
| SCHEMBL8884499 | 0.84 | EGLN2 (0.49) | EGLN2FTOEGLN1VEGFAFLT1 | |
| SCHEMBL3488780 | 0.83 | EGLN2 (0.63) | EGLN2FTOEGLN1TLR7 | |
| SCHEMBL704958 | 0.83 | FTO (1.00) | EGLN2FTOEGLN1VEGFAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248717-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2023-08-10 | — | — | US | disclosed |
| EP-3357911-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3357911-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3323807-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-2327696-A1 | Prolyl hydroxylase inhibitors and methods of use | Warner Chilcott Company, LLC (PR) | 2011-06-01 | — | — | EP | disclosed |
| US-7625927-B2 | Method of treating glaucoma | ALCON RESEARCH, LTD. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625927-B2 | Method of treating glaucoma | ALCON RESEARCH, LTD. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070203174-A1 | METHOD OF TREATING GLAUCOMA | ALCON MANUFACTURING, LTD. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203174-A1 | METHOD OF TREATING GLAUCOMA | ALCON MANUFACTURING, LTD. (US) | 2007-08-30 | — | — | US | disclosed |
| US-5620995-A | Substituted heterocyclic carboxyamides, their preparation and their use as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | disclosed |
| EP-0661269-B1 | Substituted heterocyclic carboxylic acid amides, their preparation and their use as medicaments | HOECHST AG (DE) | 1997-03-26 | — | — | EP | disclosed |
| EP-0661269-A1 | Substituted heterocyclic carboxylic acid amides, their preparation and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203174-A1 | METHOD OF TREATING GLAUCOMA | EGLN3, EGLN2, EGLN1 | EGLN2 2/4885FTO 1159/4885EGLN1 3/4885 |
| US-20230248717-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | IDO1, PDCD1, IDO2 | EGLN2 21/4885FTO 1432/4885EGLN1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.